Abstract:Sickle cell disease (SCD) is an inherited blood disorder that affects about 100,000 people in the U.S., primarily Blacks/African-Americans. A multitude of complications negatively impacts quality of life. Hydroxyurea has been FDA approved since 1998 as a disease-modifying therapy for SCD, but is underutilized. Negative and uninformed perceptions of hydroxyurea and barriers to its use hinder adherence and promotion of the medication. As the largest real-world study to date that assessed hydroxyurea use for children and adults with SCD, we gathered and analyzed perspectives of providers, individuals with SCD, and families. Participants provided information about socio-demographics, hospital and emergency admissions for pain, number of severe pain episodes interfering with daily activities, medication adherence, and barriers to hydroxyurea. Providers reported on indications for hydroxyurea, reasons not prescribed, and current laboratory values. We found that hydroxyurea use was reported in over half of eligible patients from this large geographic region in the U.S., representing a range of sickle cell specialty clinical settings and practices. Provider and patient/caregiver reports about hydroxyurea use were consistent with one another; adults 26 years and older were least likely to be on hydroxyurea; and the likelihood of being on hydroxyurea decreased with one or more barriers. Using the intentional and unintentional medication nonadherence framework, we found that, even for patients on hydroxyurea, challenges to taking the medicine at the right time and forgetting were crucial unintentional barriers to adherence. Intentional barriers such as worry about side effects and "tried and it did not work" were important barriers for young adults and adults. For providers, diagnoses other than HgbSS or HgbS-β0 thalassemia were associated with lower odds of prescribing, consistent with evidence-based guidelines. Our results support strengthening provider understanding and confidence in implementing existing SCD guidelines, and the importance of shared decision making. Our findings can assist providers in understanding choices and decisions of families; guide individualized clinical discussions regarding hydroxyurea therapy; and help with developing tailored interventions to address barriers. Addressing barriers to hydroxyurea use can inform strategies to minimize similar barriers in the use of emerging and combination therapies for SCD.

Hydroxyurea in the sickle cell disease modern era

Disease-Modifying Therapies for Sickle Cell Disease—An Overview

The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia

Experimental therapy of sickle cell disease. Use of hydroxyurea

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review

Biological Evolution in a Homozygous Adult with Sickle Cell Disease on Hydroxyurea: A Case Report

An update review of new therapies in sickle cell disease: the prospects for drug combinations

Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative

Hydroxyurea Pharmacokinetic Evaluation in Patients with Sickle Cell Disease

Ethical and Clinical Considerations in the Use of Hydroxyurea in Pregnant Women with Sickle Cell Disease

Fostering a healthier generation of children with sickle cell disease through advancements in care

Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy

Hydroxyurea reduces infections in children with sickle cell anemia in Uganda

Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan

Curative Therapies for Sickle Cell Disease

Gene Therapies for Sickle Cell Disease

Haemoglobin F modulation in childhood sickle cell disease

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell disease